Cognition Common Stock Shares Outstanding from 2010 to 2024

CGTX Stock  USD 0.40  0.01  2.44%   
Cognition Therapeutics Common Stock Shares Outstanding yearly trend continues to be fairly stable with very little volatility. Common Stock Shares Outstanding will likely drop to about 27.5 M in 2024. Common Stock Shares Outstanding is the total number of shares of a company's common stock that are currently owned by all its shareholders. View All Fundamentals
 
Common Stock Shares Outstanding  
First Reported
2010-12-31
Previous Quarter
30 M
Current Value
27.5 M
Quarterly Volatility
2.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 239.4 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Common Stock Shares Outstanding Growth Pattern

Below is the plot of the Common Stock Shares Outstanding of Cognition Therapeutics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Cognition Therapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Common Stock Shares Outstanding10 Years Trend
Slightly volatile
   Common Stock Shares Outstanding   
       Timeline  

Cognition Common Stock Shares Outstanding Regression Statistics

Arithmetic Mean23,338,723
Geometric Mean23,189,552
Coefficient Of Variation12.39
Mean Deviation2,204,231
Median21,936,629
Standard Deviation2,892,268
Sample Variance8.4T
Range8.1M
R-Value0.69
Mean Square Error4.8T
R-Squared0.47
Significance0
Slope443,348
Total Sum of Squares117.1T

Cognition Common Stock Shares Outstanding History

202427.5 M
202330 M
202229 M
202122.2 M

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Shares Outstanding30 M27.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.